|Day's Range||123.23 - 123.65|
|52 Week Range||101.51 - 123.73|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.04%|
Amgen’s (AMGN) Xgeva was launched commercially in 2010 and is marketed primarily in the US and Europe. The drug crossed the $1 billion annual revenue mark in 2013.
Long-term investors may find these buy-and-hold ETFs very appealing.